Logo Medical XPRT
Companies
Products
Services
Software
Training
Applications
Sign in
List your business
Airfinity Limited
About
  2. Companies
  3. Airfinity Limited
  4. Software
4 software found

Airfinity Limited software

Airfinity - Biorisk Surveillance Software

The world’s most comprehensive biorisk surveillance solution, providing real-time alerts and analysis on emerging outbreaks and infectious disease risks.

Airfinity - Infectious Disease Analytics (IDA) Software

The market leading platform for Infectious Disease Analytics (IDA), supporting decision making across the life science ecosystem track, analyse, simulate and predict disease outcomes.

Airfinity - IEG Policy Surveillance Software

Monitor, evaluate and anticipate the use of real world data and evidence around the globe, as well as its impact on the regulatory landscape. Real-world data (RWD) and real-world evidence (RWE) is playing an increasingly important role in how regulatory bodies and governments make healthcare decisions. However, there is currently no standardised data package to submit to regulators, HTAs and payers, making it very difficult and time consuming to collate, evaluate and understand the impact in global regulatory policy.

IEG Policy Surveillance

Monitor, evaluate and anticipate the use of real world data and evidence around the globe, as well as its impact on the regulatory landscape. Real-world data (RWD) and real-world evidence (RWE) is playing an increasingly important role in how regulatory bodies and governments make healthcare decisions. However, there is currently no standardised data package to submit to regulators, HTAs and payers, making it very difficult and time consuming to collate, evaluate and understand the impact in global regulatory policy. Airfinity’s IEG Policy Surveillance solution provides actionable insights on trends in the regulatory, real world data space by monitoring hundreds of sources across multiple languages. It selects the most relevant articles using proprietary NLP technology, which is then supplemented with expert opinions to give additional insight on emerging trends in regulatory policy.